大剂量氯吡格雷在冠心病介入治疗中的临床应用被引量：4

下载PDF

导出

摘要选择我院52例冠心病介入治疗患者,随机分为对照组(标准剂量氯吡格雷)和试验组(大剂量氯吡格雷),评估两组患者血小板聚集及出现的不良反应情况。结果介入治疗前、用药后12h及24h后,试验组血小板聚集情况明显较对照组降低,差异均有统计学意义(P<0.05);出现的不良反应较对照组未见明显改变,差异无统计学意义(P>0.05)。冠心病患者在进行介入治疗时,应用大剂量氯吡格雷能显著减少术后血栓形成率,降低不良反应发生率,有重要的临床意义。

作者韩秀江

机构地区天津南开医院心脏科

出处《现代诊断与治疗》 CAS 2013年第20期4636-4637,共2页 Modern Diagnosis and Treatment

关键词氯吡格雷冠心病介入治疗

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献2

1刘洪清,张世杨.曲美他嗪联合氯吡格雷治疗不稳定型心绞痛的临床疗效及安全性[J].航空航天医药,2010,21(4):450-451. 被引量：10
2张春英,仇兴标,侯旭敏.冠心病介入治疗患者氯吡格雷抵抗的研究进展[J].心血管病学进展,2011,32(5):663-666. 被引量：16

二级参考文献32

1梁伦昌.曲美他嗪、低分子肝素、阿托伐他汀联合治疗2型糖尿病合并不稳定型心绞痛的临床研究[J].海南医学,2005,16(9):153-154. 被引量：7
2任艺虹,盖鲁粤,杨庭树,王洪叶,王禹,邢攸红,林琳,刘春雪.改良血栓弹力图法和流式细胞测定技术对血小板活性抑制程度的比较研究[J].中华心血管病杂志,2007,35(4):366-367. 被引量：37
3Yamashita H,Ehara S,Yoshiyama M,et al.Elevated plasma levels of oxidized low density lipoprotein relate to the presence of angiographically detected complex and thrombotic coronary artery lesion morphology in patients with unstable angina[J].Circ J,2007,71(5):681-687. 被引量：1
4Hollopeter C,Jantzcn HM,Vincent D,et al.Identification of the platelet ADP receptor targeted by antithrombotic drugs[J].Nature,2001,409:202-207. 被引量：1
5Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention : the role of dual drug resistance[ J ]. J Am Coil Cardiol, 2006,47:27-33. 被引量：1
6Buonemici P, Marcucci R, Migliorini A, et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stem thrombosis[ J ]. J Am Coll Cardiol, 2007,4-9(24) :2312-2317. 被引量：1
7Malek LA, Spiewak M, Filipiak KJ, et al. Persistent platelet activation is relat- ed to very early cardiovascular events in patients with acute coronary syndromes [J]. Kardiol Pol, 2007,65:40-45. 被引量：1
8Laurent B, Laurence CJ. Adjusted clopidogrel loading doses according to vaso- dilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistence [ J ]. J Am Coll Cardiol, 2008,51(14) :1404-1411. 被引量：1
9Malek LA, Bartlomiej MD, Spiewak M, et al. Coexisting polymorphisms of and genes as a risk factor for persistent platelet activation with clopidogrel [ J ]. Circulation, 2008,72(7) :1165-1169. 被引量：1
10Fontana P, Hulot JS, Moerloose P, et al. Influence of CYP2C19 and CYP3A4 gene polymorphism on ciopidogrel responsiveness in healthy subjects [J]. Thromb Haemost, 2007,5(10) :2153-2155. 被引量：1